- Trials with a EudraCT protocol (4,485)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,485 result(s) found for: Clinical death.
Displaying page 1 of 225.
EudraCT Number: 2017-002644-32 | Sponsor Protocol Number: EFC14875 | Start Date*: 2017-11-14 | ||||||||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Ca... | ||||||||||||||||||
Medical condition: Type 2 diabetes mellitus Chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Prematurely Ended) LV (Completed) GB (Completed) HU (Completed) SE (Completed) NO (Completed) FR (Completed) NL (Completed) DK (Completed) ES (Prematurely Ended) LT (Completed) EE (Completed) PT (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003510-16 | Sponsor Protocol Number: EFC15156 | Start Date*: 2018-05-07 | ||||||||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet... | ||||||||||||||||||
Medical condition: Cardiovascular diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000779-26 | Sponsor Protocol Number: ECABUSCA12 | Start Date*: 2014-08-19 |
Sponsor Name:Asociación Instituto Biodonostia | ||
Full Title: Efficacy of subcutaneous butylscopolamine vs placebo for control to death rattle in agony. Randomized clinical trial. | ||
Medical condition: phase of agony, pre-death | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000664-31 | Sponsor Protocol Number: D169DC00001 | Start Date*: 2020-08-12 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac... | ||
Medical condition: Acute Myocardial Infarction, Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2007-004369-16 | Sponsor Protocol Number: MJ/LPGB/12/2006 | Start Date*: 2007-11-29 |
Sponsor Name:St Raphael's Hospice, Surrey | ||
Full Title: ''Evaluation of the efficacy of 'TRANS-DERMAL NITRATE' in reducing the severity of 'death-rattle' (i.e 'terminal lung secretions' ) in patients dying from end stage malignancy'' | ||
Medical condition: 'Death-rattle' (i.e 'terminal lung secretions') in adult patients dying from end-stage malignancy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005960-68 | Sponsor Protocol Number: D9319C00001 | Start Date*: 2021-07-24 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioi... | ||
Medical condition: Olaparib Maintenance Monotherapy in Participants with BRCAWild Type Ovarian Cancer Following Response toFirst-line Platinum-based Chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004160-58 | Sponsor Protocol Number: CHASAP | Start Date*: 2021-06-11 | ||||||||||||||||
Sponsor Name:Centre hospitalier intercommunal de Créteil | ||||||||||||||||||
Full Title: Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a multicenter prospective randomized double-blind placebo-controlled trial | ||||||||||||||||||
Medical condition: Pregnant women with chronic hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000802-46 | Sponsor Protocol Number: D169CC00001 | Start Date*: 2018-09-24 |
Sponsor Name:AstraZeneca AB | ||
Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur... | ||
Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2016-000671-25 | Sponsor Protocol Number: 1242-001 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S... | |||||||||||||
Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003201-26 | Sponsor Protocol Number: 1160.186 | Start Date*: 2014-07-21 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim AB | ||||||||||||||||||
Full Title: A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tr... | ||||||||||||||||||
Medical condition: Patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) DK (Completed) GR (Completed) DE (Completed) PT (Completed) HU (Completed) ES (Completed) FI (Completed) NL (Completed) CZ (Completed) AT (Completed) IT (Completed) BE (Completed) IE (Completed) SK (Completed) SI (Completed) GB (Completed) BG (Completed) HR (Completed) PL (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000996-98 | Sponsor Protocol Number: CSL112_3001 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome | |||||||||||||
Medical condition: Acute Coronary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) LV (Completed) SE (Completed) PT (Completed) FI (Completed) BE (Completed) LT (Completed) DK (Completed) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) NO (Completed) HU (Completed) FR (Completed) NL (Completed) ES (Restarted) SK (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000734-30 | Sponsor Protocol Number: D0816C00012 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germli... | |||||||||||||
Medical condition: BRCA or HRR+ Mutated Ovarian Cancer Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001498-25 | Sponsor Protocol Number: CRLX030A2301 | Start Date*: 2013-09-09 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure pa... | ||
Medical condition: Acute heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) BE (Completed) SE (Completed) IE (Completed) BG (Completed) HU (Completed) PT (Completed) LT (Prematurely Ended) IT (Completed) CZ (Completed) AT (Completed) EE (Completed) DK (Completed) ES (Completed) LV (Prematurely Ended) NL (Completed) GR (Completed) GB (Completed) PL (Completed) NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004112-60 | Sponsor Protocol Number: D9311C00001 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or with... | |||||||||||||
Medical condition: Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002683-14 | Sponsor Protocol Number: DSE-EDO-01-15-EU | Start Date*: 2017-01-12 | |||||||||||
Sponsor Name:Daiichi Sankyo Europe GmbH | |||||||||||||
Full Title: Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent p... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IE (Completed) GB (Completed) NL (Completed) DE (Completed) LT (Completed) ES (Completed) AT (Completed) HU (Completed) PT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002187-22 | Sponsor Protocol Number: 001 | Start Date*: 2005-04-05 |
Sponsor Name:Ullevål University Hospital | ||
Full Title: Scandinavian Candesartan Acute Stroke Trial | ||
Medical condition: Acute stroke (ischemic or haemoragic) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DK (Completed) BE (Completed) EE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002006-27 | Sponsor Protocol Number: CKJX839B12302 | Start Date*: 2021-11-15 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease... | |||||||||||||
Medical condition: Atherosclerotic cardiovascular disease (ASCVD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) IS (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004614-14 | Sponsor Protocol Number: BAY 59-7939/12839 | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin | |||||||||||||
Medical condition: Prevention of venous thromboembolism in patients who have been hospitalized for a medical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) DK (Completed) LT (Completed) GB (Completed) BE (Completed) AT (Completed) NL (Completed) ES (Completed) GR (Completed) PT (Completed) SI (Completed) SK (Completed) CZ (Completed) IT (Completed) PL (Completed) LV (Completed) FI (Completed) HU (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000334-17 | Sponsor Protocol Number: TRACK_001 | Start Date*: 2023-03-31 |
Sponsor Name:The George Institute of Global Health | ||
Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial | ||
Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001076-11 | Sponsor Protocol Number: CTQJ230A12301 | Start Date*: 2019-12-19 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe... | |||||||||||||
Medical condition: Cardiovascular Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
